It is estimated that 30 to 50% of heart failure patients have heart failure with preserved ejection fraction (HFpEF). Mortality is high in this patient population, and morbidity and rate of hospitalization are similar to those of heart failure patients with reduced ejection fraction (HFrEF). The management of patients with HFpEF is essentially empirical, limited, and disappointing. HFpEF is characterized by diastolic dysfunction leading to increased left ventricular (LV) filling pressures. We have previously described how mechanical energy transfer from the systole phase to the diastole phase of the cardiac cycle can potentially reduce filling pressures during the diastolic phase which may improve clinical symptoms of HFpEF. The CORolla device is a novel device anatomically designed for positioning in the left ventricle (LV) and mechanically designed to apply an outward radial force on the LV endocardium thus transferring energy from the systolic phase, in which the device contracts, gaining potential energy, to the diastolic phase from its recoil. Here we summarize the present knowledge concerning the energy transfer therapeutic approach for HFpEF, describe the CORolla device, and depict its potential future clinical indications.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10741-021-10104-xDOI Listing

Publication Analysis

Top Keywords

heart failure
16
corolla device
12
energy transfer
12
ejection fraction
12
transfer systole
8
failure preserved
8
preserved ejection
8
failure patients
8
filling pressures
8
diastolic phase
8

Similar Publications

Assessing platelet-derived extracellular vesicles for potential as therapeutic targets in cardiovascular diseases.

Expert Opin Ther Targets

January 2025

Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands.

Introduction: Cardiovascular disease (CVD) is the leading cause of death worldwide. Platelet-derived extracellular vesicles (PEV) have attracted extensive attention in cardiovascular disease research in recent years because their cargo is involved in a variety of pathophysiological processes, such as thrombosis, immune response, promotion or inhibition of inflammatory response, promotion of angiogenesis as well as cell proliferation and migration.

Areas Covered: This review explores the role of PEV in various cardiovascular diseases (such as atherosclerosis, myocardial infarction, ischemia-reperfusion injury, and heart failure), with relation to its molecular cargo (nucleic acids, bioactive lipids, proteins) and aims to provide new insights in the pathophysiologic role of PEV, and methods for preventing and treating cardiovascular diseases based on PEV.

View Article and Find Full Text PDF

Medical Problems of Chronic Hypoxia in Highlanders Living on the Tibetan Plateau.

High Alt Med Biol

January 2025

The Research Center for High Altitude Medicine, Qinghai University, Xining, China.

Ri-Li Ge. Medical problems of chronic hypoxia in highlanders living on the tibetan plateau. 00:00-00, 2024.

View Article and Find Full Text PDF

Objective: To evaluate the clinical efficacy and safety of noninvasive positive pressure ventilation combined with pressure support ventilation (NPPV-PSV) in the treatment of chronic heart failure (CHF) through a meta-analysis.

Methods: A systematic search was conducted using PubMed, Embase, Web of Science, Cochrane Library, CNKI and Wanfang databases to find randomized controlled trials and cohort studies on NPPV-PSV treatment for CHF. The period of search was set from inception until 2024.

View Article and Find Full Text PDF

Background: The purpose of this study was to investigate whether circulating pyruvate kinase M2 (PK-M2) levels are elevated in the peripheral blood and to assess their association with diagnosis and prognosis in patients with heart failure (HF).

Methods And Results: We conducted a prospective investigation involving 222 patients with HF and 103 control subjects, measuring PK-M2 concentrations using ELISA. The primary outcome, assessed over a median follow-up of 2 years (interquartile range: 776 to 926 days), was the time to the first occurrence of either rehospitalization for worsening HF or cardiovascular death.

View Article and Find Full Text PDF

Background: The study investigates the prognostic impact of sex and sex-related differences in patients hospitalized with heart failure with mildly reduced ejection fraction (HFmrEF). More data regarding the characterization of patients and their outcomes in the presence of HFmrEF are needed.

Methods And Results: Consecutive patients hospitalized with HFmrEF (ie, left ventricular ejection fraction 41%-49% and signs or symptoms of HF) were retrospectively included at one institution from 2016 to 2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!